Influence of donor/recipient HLA-matching on outcome and recurrence of hepatitis C after liver transplantation

Jan Michael Langrehr, Gero Puhl, Marcus Bahra, Maximilian Schmeding, Antonino Spinelli, Thomas Berg, Constanze Schönemann, Veit Krenn, Peter Neuhaus, Ulf Peter Neumann

Research output: Contribution to journalArticle

Abstract

The aim of this study was to analyze the effect of human leukocyte antigen (HLA) matching on outcome, severity of recurrent hepatitis C and risk of rejection in hepatitis C positive patients after liver transplantation (LT). In a retrospective analysis, 165 liver transplants in patients positive for hepatitis C virus (HCV) with complete donor/recipient HILA typing were reviewed for recurrence of HCV and outcome. Follow-up ranged from 1 to 158 months (median, 74.5 months). Immunosuppression consisted of either cyclosporine-A- or tacrolimus-based quadruple induction therapy including or an interleukin 2-receptor antagonist. Protocol liver biopsies were performed after 1, 3, 5, 7, and 10 years and staged according to the Scheuer scoring system. The overall 1-, 5-, and 10-year graft survival figures were 81.8%, 69.11 and 62%, respectively. There was no correlation in the study population between number of HLA mismatches and graft survival. The number of rejection episodes increased significantly in patients with more HLA mismatches (P <0.05). In contrast to this, the fibrosis progression was significantly faster in patients with 0-5 HLA mismatches compared to patients with a complete HLA mismatch. In conclusion, HLA matching did not influence graft survival in patients after LT for end-stage HCV infection, however, despite less rejection episodes, the fibrosis progression increased in patients with less HLA mismatches within the first year after LT.

Original languageEnglish
Pages (from-to)644-651
Number of pages8
JournalLiver Transplantation
Volume12
Issue number4
DOIs
Publication statusPublished - Apr 2006

Fingerprint

Hepatitis C
HLA Antigens
Liver Transplantation
Tissue Donors
Recurrence
Graft Survival
Hepacivirus
Fibrosis
Interleukin-2 Receptors
Liver
Tacrolimus
Virus Diseases
Immunosuppression
Cyclosporine
Transplants
Biopsy
Population

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Influence of donor/recipient HLA-matching on outcome and recurrence of hepatitis C after liver transplantation. / Langrehr, Jan Michael; Puhl, Gero; Bahra, Marcus; Schmeding, Maximilian; Spinelli, Antonino; Berg, Thomas; Schönemann, Constanze; Krenn, Veit; Neuhaus, Peter; Neumann, Ulf Peter.

In: Liver Transplantation, Vol. 12, No. 4, 04.2006, p. 644-651.

Research output: Contribution to journalArticle

Langrehr, JM, Puhl, G, Bahra, M, Schmeding, M, Spinelli, A, Berg, T, Schönemann, C, Krenn, V, Neuhaus, P & Neumann, UP 2006, 'Influence of donor/recipient HLA-matching on outcome and recurrence of hepatitis C after liver transplantation', Liver Transplantation, vol. 12, no. 4, pp. 644-651. https://doi.org/10.1002/lt.20648
Langrehr, Jan Michael ; Puhl, Gero ; Bahra, Marcus ; Schmeding, Maximilian ; Spinelli, Antonino ; Berg, Thomas ; Schönemann, Constanze ; Krenn, Veit ; Neuhaus, Peter ; Neumann, Ulf Peter. / Influence of donor/recipient HLA-matching on outcome and recurrence of hepatitis C after liver transplantation. In: Liver Transplantation. 2006 ; Vol. 12, No. 4. pp. 644-651.
@article{3c777834166848328f30ac01fe1a928b,
title = "Influence of donor/recipient HLA-matching on outcome and recurrence of hepatitis C after liver transplantation",
abstract = "The aim of this study was to analyze the effect of human leukocyte antigen (HLA) matching on outcome, severity of recurrent hepatitis C and risk of rejection in hepatitis C positive patients after liver transplantation (LT). In a retrospective analysis, 165 liver transplants in patients positive for hepatitis C virus (HCV) with complete donor/recipient HILA typing were reviewed for recurrence of HCV and outcome. Follow-up ranged from 1 to 158 months (median, 74.5 months). Immunosuppression consisted of either cyclosporine-A- or tacrolimus-based quadruple induction therapy including or an interleukin 2-receptor antagonist. Protocol liver biopsies were performed after 1, 3, 5, 7, and 10 years and staged according to the Scheuer scoring system. The overall 1-, 5-, and 10-year graft survival figures were 81.8{\%}, 69.11 and 62{\%}, respectively. There was no correlation in the study population between number of HLA mismatches and graft survival. The number of rejection episodes increased significantly in patients with more HLA mismatches (P <0.05). In contrast to this, the fibrosis progression was significantly faster in patients with 0-5 HLA mismatches compared to patients with a complete HLA mismatch. In conclusion, HLA matching did not influence graft survival in patients after LT for end-stage HCV infection, however, despite less rejection episodes, the fibrosis progression increased in patients with less HLA mismatches within the first year after LT.",
author = "Langrehr, {Jan Michael} and Gero Puhl and Marcus Bahra and Maximilian Schmeding and Antonino Spinelli and Thomas Berg and Constanze Sch{\"o}nemann and Veit Krenn and Peter Neuhaus and Neumann, {Ulf Peter}",
year = "2006",
month = "4",
doi = "10.1002/lt.20648",
language = "English",
volume = "12",
pages = "644--651",
journal = "Liver Transplantation",
issn = "1527-6465",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

TY - JOUR

T1 - Influence of donor/recipient HLA-matching on outcome and recurrence of hepatitis C after liver transplantation

AU - Langrehr, Jan Michael

AU - Puhl, Gero

AU - Bahra, Marcus

AU - Schmeding, Maximilian

AU - Spinelli, Antonino

AU - Berg, Thomas

AU - Schönemann, Constanze

AU - Krenn, Veit

AU - Neuhaus, Peter

AU - Neumann, Ulf Peter

PY - 2006/4

Y1 - 2006/4

N2 - The aim of this study was to analyze the effect of human leukocyte antigen (HLA) matching on outcome, severity of recurrent hepatitis C and risk of rejection in hepatitis C positive patients after liver transplantation (LT). In a retrospective analysis, 165 liver transplants in patients positive for hepatitis C virus (HCV) with complete donor/recipient HILA typing were reviewed for recurrence of HCV and outcome. Follow-up ranged from 1 to 158 months (median, 74.5 months). Immunosuppression consisted of either cyclosporine-A- or tacrolimus-based quadruple induction therapy including or an interleukin 2-receptor antagonist. Protocol liver biopsies were performed after 1, 3, 5, 7, and 10 years and staged according to the Scheuer scoring system. The overall 1-, 5-, and 10-year graft survival figures were 81.8%, 69.11 and 62%, respectively. There was no correlation in the study population between number of HLA mismatches and graft survival. The number of rejection episodes increased significantly in patients with more HLA mismatches (P <0.05). In contrast to this, the fibrosis progression was significantly faster in patients with 0-5 HLA mismatches compared to patients with a complete HLA mismatch. In conclusion, HLA matching did not influence graft survival in patients after LT for end-stage HCV infection, however, despite less rejection episodes, the fibrosis progression increased in patients with less HLA mismatches within the first year after LT.

AB - The aim of this study was to analyze the effect of human leukocyte antigen (HLA) matching on outcome, severity of recurrent hepatitis C and risk of rejection in hepatitis C positive patients after liver transplantation (LT). In a retrospective analysis, 165 liver transplants in patients positive for hepatitis C virus (HCV) with complete donor/recipient HILA typing were reviewed for recurrence of HCV and outcome. Follow-up ranged from 1 to 158 months (median, 74.5 months). Immunosuppression consisted of either cyclosporine-A- or tacrolimus-based quadruple induction therapy including or an interleukin 2-receptor antagonist. Protocol liver biopsies were performed after 1, 3, 5, 7, and 10 years and staged according to the Scheuer scoring system. The overall 1-, 5-, and 10-year graft survival figures were 81.8%, 69.11 and 62%, respectively. There was no correlation in the study population between number of HLA mismatches and graft survival. The number of rejection episodes increased significantly in patients with more HLA mismatches (P <0.05). In contrast to this, the fibrosis progression was significantly faster in patients with 0-5 HLA mismatches compared to patients with a complete HLA mismatch. In conclusion, HLA matching did not influence graft survival in patients after LT for end-stage HCV infection, however, despite less rejection episodes, the fibrosis progression increased in patients with less HLA mismatches within the first year after LT.

UR - http://www.scopus.com/inward/record.url?scp=33645552212&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645552212&partnerID=8YFLogxK

U2 - 10.1002/lt.20648

DO - 10.1002/lt.20648

M3 - Article

C2 - 16555324

AN - SCOPUS:33645552212

VL - 12

SP - 644

EP - 651

JO - Liver Transplantation

JF - Liver Transplantation

SN - 1527-6465

IS - 4

ER -